PT - JOURNAL ARTICLE AU - Sudarsan Pothal AU - Ipsita Samantaray AU - Sashi Bhusan Biswal TI - Metformin as an adjunct in treatment of Pulmonary Tuberculosis in Non-Diabetic patients AID - 10.1183/13993003.congress-2021.OA1601 DP - 2021 Sep 05 TA - European Respiratory Journal PG - OA1601 VI - 58 IP - suppl 65 4099 - http://erj.ersjournals.com/content/58/suppl_65/OA1601.short 4100 - http://erj.ersjournals.com/content/58/suppl_65/OA1601.full SO - Eur Respir J2021 Sep 05; 58 AB - Background: Development of novel Host Directed Therapies, aimed at optimizing the host’s response against the mycobacterium, in combination with existing antibiotics is the need of the hour. Pre-clinical evidence of recent in vitro study showed Metformin modulate immune function & gene transcription involved innate response to Mycobacterium Tuberculosis in healthy subjects.Aim: To study the activity of metformin as adjunct in combination with standard anti-TB treatment (ATT) regimen, in terms of time to sputum conversion in newly diagnosed smear positive pulmonary TB.Methods: A randomised, open-labelled, controlled clinical trial was conducted. Study recruited 80 newly diagnosed non-diabetic pulmonary TB patients in control group (only ATT for whole duration) and metformin group (Metformin 500 mg with ATT for first 2 months and only ATT for the rest 4 months). All patients of both groups were followed up for sputum smear examination, fasting blood sugar & GeneXpert  for drug resistance pattern (at the end of 2 months) & tolerability and adverse events.Result: The average time taken for sputum smear conversion was significantly lower in the Metformin group (3.59±1.74 weeks) in comparison with the control group (4.26±2.31 week), 2.67 % of Metformin group found Rifampicin resistance at the end of the intensive phase whereas 8 % in control group. There was no significant difference noted in the fortnightly FBS values between the two groups. No serious adverse reactions were encountered in either of the groups.Conclusion: Metformin added to anti-TB treatment inPulmonary TB significantly reduced the time for sputum smear concersion & decrease refampicin resistance.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA1601.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).